Tessera Therapeutics/X
Dec 12, 2024, 11:16
Preclinical data presented at the 66th ASH Annual Meeting – Tessera Therapeutics
Tessera Therapeutics shared a post on LinkedIn:
“Today we announced preclinical data presented at the 66th American Society of Hematology (ASH) Annual Meeting, highlighting advances in our in vivo therapies for sickle cell disease (SCD) and T cell therapies. Read more here.”
More posts featuring ASH24.
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Sep 4, 2025, 20:03
Sep 4, 2025, 19:35
Sep 4, 2025, 16:17
Sep 4, 2025, 16:08
Sep 4, 2025, 15:59
Sep 4, 2025, 15:51
Sep 4, 2025, 15:49